Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

2seventy bio (TSVT)

2seventy bio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TSVT
DateTimeSourceHeadlineSymbolCompany
06/06/202400:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
06/06/202400:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
23/05/202412:00Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
16/05/202423:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
09/05/202421:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSVT2seventy bio Inc
08/05/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
08/05/202412:00Business Wire2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
03/05/202412:00Business Wire2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:TSVT2seventy bio Inc
05/04/202414:05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNASDAQ:TSVT2seventy bio Inc
01/04/202412:30Business Wire2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronNASDAQ:TSVT2seventy bio Inc
20/03/202421:04Business Wire2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsNASDAQ:TSVT2seventy bio Inc
15/03/202422:27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNASDAQ:TSVT2seventy bio Inc
07/03/202421:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TSVT2seventy bio Inc
05/03/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/03/202412:00Business Wire2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
01/03/202412:00Business Wire2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202421:05Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202412:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
05/02/202411:59Business WireBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyNASDAQ:TSVT2seventy bio Inc
02/02/202421:54Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TSVT2seventy bio Inc
30/01/202414:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:TSVT2seventy bio Inc
30/01/202412:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
30/01/202412:01Business Wire2seventy bio Announces New Strategic Path ForwardNASDAQ:TSVT2seventy bio Inc
05/01/202421:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSVT2seventy bio Inc
12/12/202312:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
12/12/202300:30Business WireAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3NASDAQ:TSVT2seventy bio Inc
11/12/202312:00Business Wire2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)NASDAQ:TSVT2seventy bio Inc
06/12/202319:00Business Wire2seventy bio Reiterates Commitment to Maximizing Shareholder ValueNASDAQ:TSVT2seventy bio Inc
01/12/202311:49Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
01/12/202311:46Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
 Showing the most relevant articles for your search:NASDAQ:TSVT

Your Recent History

Delayed Upgrade Clock